Rosen Law Firm Reminds Regeneron Pharmaceuticals Investors of Lead Plaintiff Deadline
January 23, 2025
NEW YORK, NY / ACCESS Newswire / January 23, 2025 /
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), of the important March 10, 2025 lead plaintiff deadline.
If you purchased Regeneron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company’s product portfolio includes medicines for eye diseases, high LDL-cholesterol, atopic dermatitis, and a rare inflammatory condition.
During the Class Period, it is alleged that Regeneron made false and misleading statements about the efficacy and safety of certain drugs, leading to inflated stock prices. As a result, investors who purchased Regeneron securities during this time may have suffered financial losses.
Investors who wish to participate in the lead plaintiff deadline must submit their claims by March 10, 2025. This deadline is crucial for investors to seek compensation for any losses incurred during the Class Period.
For more information on the lead plaintiff deadline and how to participate, investors are encouraged to contact Rosen Law Firm or visit the firm’s website.
How This Will Affect Me:
As an investor in Regeneron Pharmaceuticals, Inc., it is important to be aware of the lead plaintiff deadline set by Rosen Law Firm. If you purchased Regeneron securities during the Class Period, you may be eligible for compensation through a contingency fee arrangement. By participating in the lead plaintiff deadline, you have the opportunity to seek restitution for any financial losses incurred as a result of alleged false and misleading statements made by the company.
How This Will Affect the World:
The outcome of the securities class action against Regeneron Pharmaceuticals, Inc. could have a broader impact on the biotechnology industry as a whole. Investors and stakeholders in the pharmaceutical sector will be closely monitoring the developments of this case, as it may set a precedent for how companies are held accountable for their disclosures and representations to investors. The resolution of this lawsuit could also influence regulations and guidelines governing the pharmaceutical industry, ultimately shaping the future of drug development and commercialization.
Conclusion:
Investors in Regeneron Pharmaceuticals, Inc. should take note of the lead plaintiff deadline set by Rosen Law Firm and consider their options for seeking compensation for potential losses incurred during the Class Period. The outcome of this securities class action may not only impact individual investors, but also have broader implications for the pharmaceutical industry and regulatory landscape. Stay informed and stay proactive in protecting your investment interests.
